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Abstract
Focused ultrasound has been gaining impetus in the non-invasive treatment of
different diseases. This includes various cancers, essential tremor, and Parkinson’s
disease, to name a few. The ability of focused ultrasound to concentrate energy at
a single focal point away from the surface of the transducer allows for therapies to
reach a targeted region in a non-invasive manner.
Of the different diseases that can be treated using focused ultrasound, brain
morbidities have been garnering special interest in ongoing research. This can be
attributed to focused ultrasound being able to access any area of interest in the brain
(for example, a tumor), without the risk of disturbing surrounding critical structures.
In this thesis, we discuss the application of focused ultrasound for the treatment
of various brain diseases. We also look at the development and use of preclinical
instrumentation for advancing novel therapies in animal models to clinical translation.
Since focused ultrasound involves the deposition of energy at the target region in
the brain, care must be taken that there are no downstream effects of these therapies
on the central nervous system. Change in the cerebrospinal fluid (CSF) pressure is an
example of an important effect that may be seen as a result of focused ultrasound-
based therapies, a change which could cause detrimental effects of its own. Here,
we also look at the development and potential use of a fiber-optic based sensor to
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Acoustic waves with frequencies above the human audible range, that is, 20kHz
are referred to as ultrasound. In the field of medicine, ultrasound is broadly used in
imaging and therapy. When used in imaging (sonography), a transducer (piezo-electric
crystals that vibrate, causing the medium in contact with it to vibrate at the same
frequency) emit ultrasonic waves in the frequency range of 2 to 18 MHz. A receiver
located near the transducer picks up waves reflected from the tissue being imaged
and converts it into an electrical signal [1]. Sonography should cause no physiological
effects during its application. Therefore, the Food and Drug Administration (agency
responsible for public health) allows the use of ’diagnostic’ ultrasound within certain
acceptable limits, as listed in the paper by Nelson et al [2].
During focused ultrasound (FUS), acoustic waves are generated by a transducer.
The transducer(s) is designed to converge these acoustic waves at a focal point, which
is often at the target tissue location. The focal point is where the transducer generates
its maximum acoustic energy [3]. This acoustic energy can be used in a variety
of different therapeutic applications. Focused ultrasound can be used to carry out
thermal ablation, blood brain barrier opening, histotripsy, sonodynamic therapy,
radiosensitization, or immunomodulation (Figure 1-1) [4].
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One of the biggest advantages of focused ultrasound-based therapies is that it
can be used to non-invasively access a target structure in the body. The potential to
access structures of interest without disturbing surrounding eloquent brain matter is
what has drawn huge interest to this therapeutic modality.
Figure 1-1. FUS Applications: some therapeutic effects achievable in the brain (repro-
duced with permission from [4])
Understanding focused ultrasound terminology and parame-
ters
Before we dive into the focused ultrasound and its applications, let us understand
the parameters that govern focused ultrasound treatments (visualized in Figure 1-2):
• Frequency: is the number of ultrasound waves generated by the transducer
per second. It is also the rate at which the molecules of the medium coupled
with the transducer vibrate.
• Burst Length: is the time duration for which the transducer is active and
emitting acoustic energy.
• Inter-pulse Interval: is the period of rest between two successive bursts.
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• Pulse Repetition Interval: is the sum of the burst length and inter-pulse
interval.
• Duty Cycle: is the ratio of the burst length to the pulse repetition period. It
signifies the percentage of time the transducer is active.
• Time Duration: This is the total duration for which the ultrasound transducer
will sonicate. It consists of a burst followed by an inter-pulse interval followed
by a burst, repeated in succession.
Figure 1-2. Ultrasound parameters
Now, with the basic understanding of focused ultrasound and its accompanying
parameters, the different applications of focused ultrasound can be explored.
Applications of Focused Ultrasound in Neurology
Blood-Brain Barrier Opening
The blood-brain barrier (BBB) is a lining of packed endothelial cells along the
blood vessels in the brain which form tight junctions. It only allows the exchange of
small molecules (nutrients, oxygen, and waste) between the cerebrospinal fluid and
the blood [5]. Drugs that are used in the treatment of brain tumors (chemotherapy),
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Alzheimer’s disease, or Parkinson’s disease are typically too large in size to cross the
BBB [6]. Therefore, in order to allow drugs to reach the target tissue in the brain,
the BBB needs to be opened. However, this opening cannot be permanent to ensure
that after the drug is delivered, the BBB can return to performing its functions.
The BBB can be transiently opened at the site of the target structure to allow
passage of drug molecules. Different methods are being investigated for this purpose.
These include ultrasound, photochemical internalization, photodynamic therapy, and
osmotic opening. Of these, focused ultrasound is the most widely researched method
[7, 8].
Focused ultrasound in conjunction with microbubbles (eg: Optison™, Definity)
are used to reversibly open the BBB without causing damage to the parenchymal cells
[9]. The microbubbles, which are micron-diameter shells filled with gas, are injected
intravenously and ultrasound applied transcranially. At the beam focus, the acoustic
waves cause the microbubbles to vibrate, and their ultimate cavitation in turn opens
the BBB at the target site. The drug is then delivered intravenously as a bolus. Due
to the inherent nature of the BBB, it closes as early as 6 hours after the application
of focused ultrasound, when optimal parameters are used [10].
Previous studies on animals, both mice and rabbits, have used MRI to guide the
ultrasound and, with the help of contrast agents, to image the BBB opening. These
studies have shown the successful opening and closing of the BBB. Studies have also
shown the increased amounts of drugs being delivered to the tumor site through
the open BBB when compared to sham procedure controls. Minimum damage to
surrounding tissue from the ultrasound, microbubbles, or drugs were also verified
[11–15].
Human studies have been performed with considerable success [16]. From 2015-19,
Kullervo et al. [17] conducted a feasibility and safety study to treat primary brain
tumors in humans using this method. This study was conducted with 5 patients with
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gliomas who had not received any previous treatment. They received the treatment,
that is, liposomal doxorubicin (1 patient) or temozolomide (4 patients) a day prior to
their scheduled surgical resections. Focused ultrasound was used to open the BBB to
provide these agents access to the tumor. The BBB opening was visually confirmed
via MRI scans facilitated by contrast agents. Histological analysis of the tumor and
peritumor sample obtained during resection showed the presence of the drug in the
treatment group. None of the patients suffered adverse effects.
Ablation
Extremely high (hyperthermia) or low (hypothermia) temperatures, when applied
to tissue, can result in death, also known as necrosis. Temperatures below -41°C and
above 60°C result in instantaneous necrosis for most cell types. Thermal ablation is
aimed at killing the entire tumor mass along with a 5-10 mm margin of surrounding
normal tissue in situ. Over the course of several months, the body can then absorb
this necrotic mass [18].
High Intensity Focused Ultrasound (HIFU) is one of many methods available to
perform thermal ablation [18]. During HIFU, the acoustic waves converge at a focal
point, which is often at the tumor location. The acoustic energy at the focal point is
absorbed by the tissue, resulting in heat generation. Therefore, lesions are formed by
coagulation necrosis due to the extreme state of hyperthermia at the focal point [19].
To cause tissue temperatures to be at least 60°C at the focal point in vivo in the
presence of the human skull, the frequency of the ultrasonic wave should be at least
650 kHz [20]. The human skull is considerably thick [21], and significantly attenuates
waves of frequencies required to perform thermal ablation [22]. Therefore, if ablation
using HIFU is to be carried out in vivo, high power would be required to allow the
acoustic wave to propagate through the skull. This would result in the skull absorbing
these attenuated waves and heating up considerably [23] making non-invasive thermal
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ablation using focused ultrasound significantly hard to achieve.
Therefore, research into minimally invasive techniques to facilitate thermal ablation
using focused ultrasound is currently underway. Manbachi et al. [24] designed an
ultrasound-guided focused ultrasound transducer to be placed inside the BrainPath,
which is used to gain atraumatic access to regions of the brain. The BrainPath trocar
could be placed in a relatively insensitive area of the brain and the transducer could
be used to ablate the tumor from a distance, potentially bypassing sensitive tissues.
Successful in vitro studies were performed and will be followed up by cadaveric studies.
Canney et al. developed an MRI-guided 56 element interstitial ultrasound applicator
to ablate both primary and secondary brain tumors. In vitro studies were performed
with tissue-mimicking phantoms along with simulations to demonstrate the efficacy of
the device [25]. Despite non-invasive ablation being extremely hard to achieve, Werner
et al. performed [20] the first non-invasive thermal ablation of a glioblastoma tumor
using transcranial focused ultrasound in 2014, significantly reducing the tumor volume.
In this study temperatures lower than 60°C were achieved causing coagulation over
time instead of instantaneously, thus increasing sonication time.
Histotripsy
There are nano-sized gas pockets that exist throughout our body. When focused
ultrasound of very high pressure is applied to tissue, these naturally-occurring nano-
sized air pockets expand and collapse in rapid succession, forming a bubble cloud.
This phenomenon is known as cavitation [26]. When cavitation occurs, the cells in
the vicinity experience high amounts of shear stress. If this shear stress experienced
is above the intrinsic threshold for a sufficient duration of time it can cause cell
destruction [27]. After destruction, the cellular debris is cleared out by the body
within 2 weeks. This process of controlling cavitation mechanically to ablate target
tissue is known as histotripsy [28].
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Since histotripsy involves cellular destruction at the site of the bubble cloud
formation, the boundaries of the resulting lesion formation are unlike thermal ablation
(i.e. thermal spread causes irregular boundary formation) [29]. Since histotripsy
involves sonications with very high power but a small duty cycle, the heating of the
skull can be minimized, and it can therefore be used in the brain as a completely
non-invasive therapy.
Additionally, the cellular debris formed has been shown to elicit an immune
response. This could not only help prevent recurrence of the tumor, but also shrink
metastatic tumor masses (discussed in detail below in Immunomodulation).
Histotripsy is currently in clinical trials for the treatment of liver tumors [30].
Research for translation of its application to treat brain tumors is underway. The
main goal of the research is to optimize histotripsy parameters, such as correcting for
aberrations caused due to the presence of the skull, using imaging modalities to guide
the treatment, and selectively sensitizing the tumor tissue (nano-particle mediated
histotripsy), for future treatment procedures in the brain [31, 32].
Immunomodulation
Immunotherapy involves treating a disease by suppressing or activating the immune
system, and has been heavily investigated in the field of cancer research [33]. For
tumors that recur, the need for tumor-specific antigens is great. Focused ultrasound
demonstrates the potential to cause an immune response to prevent recurrences by
inducing tumor-specific antigens.
Focused ultrasound performed with parameters causing mechanical lysis or thermal
coagulation of tumor cells primarily results in the release of danger signals known as
heat shock protein 60 (hsp60) and adenosine triphosphate (ATP), as seen in an in vitro
study performed by Hu et al [34]. The release of these signals was five times greater
for mechanical HIFU (histotripsy) than thermal HIFU. This is because the thermal
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HIFU parameters elicited thermal necrosis of tumor cells primarily causing the release
of these danger signals. However, this release was stable throughout and did not
progress as treatment continued. Additionally, the maturation of antigen-presenting
cells (APCs) due to these released danger signals was much more evident in histotripsy
than thermal ablation. This shows promise that the FUS-induced immune response
of cancer cells can be used as a prevention for the recurrence of brain tumors (i.e.,
glioblastoma multiforme).
Radiosensitization
Radiation therapy (RT) uses high doses of radiation to kill cancer cells and to slow
tumor growth by destroying its DNA [35]. Radiation is part of the clinical treatment
regimen in brain tumor treatment. Radiation in combination with hyperthermia
(HT) has been investigated due to the increased sensitization to radiation under such
conditions [36]. Unfortunately, the only way to achieve hyperthermia in the tumor
region was via invasive heat probes. Due to its invasive nature, RT+HT was less
popular than other cancer therapies (for example: surgical resection, chemotherapy)
[37]. Due to the advancements in focused ultrasound technology, there is new interest in
radiosensitization, as FUS can be applied transcranially to increase tumor temperature
to hyperthermia requirements (42°C). There are several processes believed to explain
how HT increases the efficacy of radiation. Previous studies have shown that HT
increases perfusion and oxygenation in/around the tumor, activates immune response,
causes cell death, and most importantly, reduces the ability for the cancerous DNA to
repair itself [35].
Sonodynamic Therapy
Glioblastoma multiforme (GBM) is the most common malignant primary brain
tumor. The tumor is aggressive, invasive, and infiltrating in nature, which also leads
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to one of the shortest survival rates among cancers. The average survival is 12-15
months and only about 11% of patients survive 5 years. Due to the microstructures
GBM develops, total surgical resection is difficult, leading to a high recurrence rate.
[38]
A promising treatment for GBM involves the use of a sonosensitizing agent which
becomes cytotoxic to malignant tumor cells once exposed to focused ultrasound, oth-
erwise known as sonodynamic therapy (SDT). For brain tumors, especially GBMs,
5-aminolevulinic acid (5-ALA) has been investigated as a sonosensitizing agent [39].
5-ALA is a naturally occurring intermediate in the pathway by which heme is synthe-
sized, and when orally administered to GBM patients, it acts like a pro-agent that
accumulates in gliomas and within surrounding cancer cells outside the tumor bulk
[40]. GBMs become highly vascularized by sprouting new capillaries from pre-existing
vessels, significantly affecting the BBB within their region, and ultimately allowing for
GBM uptake of 5-ALA [41]. 5-ALA is preferential taken up GBM cells [42–44]. Once
inside GBM cells, 5-ALA is converted to fluorescent protoporphyrin (PpIX), which
allows it to be regularly used in guided resection surgeries for visualization purposes
[45].
There are eight enzymatic steps involved in the heme pathway (biochemical pathway
responsible for heme synthesis in blood [46]) between the mitochondria and cytoplasm.
CPgenIII is a product of the fifth enzyme, uroporphyrinogen III decarboxylase, and
it enters the mitochondria from the cytoplasm to serve as the immediate precursor
for PpIX. This process is energy-dependent, so CPgenIII movement requires an
ATP-binding cassette transporter: ABCB6. GBM cells have been shown to possess
significantly greater levels of ABCB6 than healthy cells [42–44, 47, 48]. The mechanical
interaction of ultrasound and PpIX within the tumor causes the generation of reactive
oxygen species (ROS), producing direct cytotoxicity in malignant cells [49].
There are several benefits of SDT over thermal ablation when it comes to treating
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GBM. One being that little to no temperature rise in the tissue is needed. The
production of ROS means that FUS is not needed to produce elevated temperature
values, which are typically required for hyperthermia and ablation treatments [4].
Therefore, far less energy is required for SDT and there is minimal risk for patient
scalp overheating (a common side effect of brain tumor ablation) [24, 49]. Another
advantage of SDT over ablation is that it does not need to be pulsed, meaning the
procedure can be continuous and faster. In addition, due to the unwanted heating of
the skull, ablation is usually limited to tumors in the center of the brain, whereas,
SDT is feasible for tumors located in any part of the brain.
Comparing Focused Ultrasound Applications with
Each Other and Current Clinical Treatments
When it comes to treating brain tumors, there are three conventional standards
of care - surgical resection, chemotherapy, and radiation therapy. Surgical Resection,
although invasive, is a preferred form of therapy with the aim of removing the
entire tumor volume. However, surgical resection is limited by the location of the
tumor. The presence of surrounding eloquent structures may prevent surgical access
to the tumor. Additionally, surgical resection may not remove all of the tumor micro-
structures, causing the tumor to recur [50]. Therefore, non-invasive therapies are either
used in conjunction with or in place of surgical resection. This commonly includes
chemotherapy and radiation therapy. As previously described, most chemotherapeutic
drugs used to treat brain tumors are prevented by the BBB from reaching the tumor in
the brain [51]. Radiation therapy, although able to reach the tumor site non-invasively,
poses a risk of harming healthy cells and causing multiple, undesired side-effects.
These drawbacks of conventional therapies allow focused ultrasound to be inves-
tigated for the treatment of brain tumors. Thermal ablation and histotripsy can
be used to perform ’non-invasive resection’. The end-goal of these two applications
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would be to kill the entire tumor mass (including the micro-structures) while trying
to minimize collateral damage. In cases where one wishes to explore the efficacy of
chemotherapeutic drugs on the tumor before considering resections, BBB disruption to
aid chemotherapy shows promise. SDT shows promise for preferentially killing tumor
cells while sparing healthy cells, especially at the tumor border where micro-structures
exist in such close proximity to the healthy cells.
Although focused ultrasound research is continually progressing in the field of
neuro-oncology, it also is being utilized for treating other neurological diseases, like
Alzheimer’s disease, Parkinson’s disease, and essential tremor. Focused ultrasound has
been FDA approved to treat essential tremor non-invasively by ablating the ventral
intermediate nucleus in the thalamus [52]. Focused ultrasound has also been approved
to open the BBB for the treatment of Parkinson’s disease [53]. The FDA has also
approved clinical trials for blood-brain barrier opening to treat Alzheimer’s disease
and even tumors [54]. Overall focused ultrasound shows great promise for the safe
and efficacious treatment of neurological diseases.
Potential Downstream Effects of Focused Ultrasound
Focused ultrasound is an exciting field of research - with all its current and potential
benefits. However, care must be taken to ensure that there are no undesirable side
effects of these focused ultrasound-based treatments. This is especially critical in
brain applications because there is close to zero tolerance for collateral damage.
Overheating of the skull
Thermal ablation using focused ultrasound requires appreciable power to be
delivered at the focus point continuously (100% duty cycle) to allow tissues to reach an
instantaneous coagulation temperature of 60°C. In "transcranial" focused ultrasound,
this energy has to pass through the skull, and as previously discussed, the skull heavily
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attenuates ultrasound waves, by absorbing them. The ultrasound energy that is
absorbed by the skull during thermal ablation can cause considerable heating of the
skull and tissues within the vicinity of the skull [22, 23].
Therefore, ablation of tumors generally requires a portion of the skull that lies
in the ultrasound beam path to be removed (by performing a craniotomy). If this
craniotomy is not performed, then the power delivered to the focus would need to
be reduced (to prevent heating of the skull). Under these circumstances, the tissue
would not be able to reach 60°C quickly and therefore the time taken for the tissue
to coagulate would be longer. This would cause the treatment duration to increase
considerably [20].
Additionally, by leaving the skull intact, only centrally located tumors can be
treated. This is because energy increases closer to the focal spot. For tumors near
the skull, the focus would be required to be formed closer to the skull. This would
cause a higher degree of heating of the skull, and therefore, increase the chances of
damaging the skull and surrounding tissue [55].
Killing healthy tissue
In applications of focused ultrasound that cause direct death of structures in
the brain (for instance, brain tumors), care must be taken to monitor and minimize
collateral damage, that is, damage to healthy brain cells and tissues.
In thermal ablation, when the targeted tissue is heated, the thermal energy
generated at the focal spot can diffuse outwards, an effect known as thermal spread
[56]. This causes lesions with irregular boundary shapes [24, 56]. Care must be taken
that this thermal spread does not encroach upon and kill healthy tissue in the brain.
In histotripsy, since focused ultrasound-induced cavitation is used to kill cells in
the target structure, the boundaries of the lesion are sharp (unlike thermal ablation).
However, in an attempt to, for example, mechanically kill all the tumor cells in a
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tumor (to prevent recurrence), the bubble-cloud might be brought precariously close
to healthy tissue at the tumor margin, therefore risking collateral damage.
In sonodynamic therapy, the reactive oxygen species that cause cell death are
produced intracellularly [57]. It is still unclear whether the reactive oxygen species
that are produced, during cell disruption, can diffuse out and extracellularly cause
cell death. If so, care must be taken especially at the tumor margins.
Increasing cerebrospinal fluid (CSF) pressure
Since focused ultrasound involves delivering energy to a targeted location in
the brain, care must be taken to ensure that it does not cause any major changes
systemically in the brain or spinal cord. One important parameter that should be







Small animal studies are a vital step in translating focused ultrasound - based
treatments to the clinic. For "non-neuro" therapeutic applications of focused ul-
trasound, ultrasound imaging can be used to guide the therapy in real time. For
transcranial focused ultrasound applications in the brain, ultrasound imaging cannot
be used because of the presence of the skull (which heavily attenuates acoustic waves).
Therefore, Magnetic Resonance Imaging (MRI) can be utilized as an imaging modality
to guide focused ultrasound therapies in the brain. Although it is not as immediate
as ultrasound [58], MRI allows for high resolution imaging of brain anatomy to guide
targeting of the structure of interest. It can also be used to view the therapeutic
effects of focused ultrasound both during and after treatment.
In order to employ MRI as an imaging modality in focused ultrasound treatments,
the focused ultrasound system, at least the transducer and guiding system, should be
MRI-compatible.
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The RK-300 by FUS Instruments
The RK-300, developed by FUS Instruments, is an MRI-guided Focused Ultrasound
System that can be used to perform small animal studies including BBB opening,
sonodynamic therapy, ablation, and neuromodulation.
The RK-300 in the Department of Radiology (Johns Hopkins School of Medicine),
can be broken down into three subsystems - Hardware, Software, and Accompanying
Components. The following sections briefly describe these three subsystems.
Hardware
The hardware can be divided into the front-end and back-end. The front-end is the
RK-300 arm (Figure 2-1.b) which consists of a single element transducer with a center
frequency of 1.0106 MHz. The concave surface of the transducer results in the focus
being geometrically fixed. The calculation of the focal distance for the transducer on
the RK-300 is shown in Figure 2-2. The concave surface is the transducer and the
apex of the right-angle triangle is the focus.
The focus is an ellipsoid that has a long axis around 9.3 mm in the direction of
ultrasound propagation and a short axis of 1.7 mm perpendicular to the direction
of ultrasound propagation (measured with a hydrophone). Changing the frequency
changes the spatial extent of the elliptical focal region, but the focus itself remains
centered at the geometric center (calculated in Figure 2-2) of the spherical cap
transducer. This information was provided through correspondence with the company.
The positioning system also located on the arm consists of two motors that
mechanically steer the focus by physically moving the transducer. In addition to the
transducer and motor, the arm is designed to support a small animal under anesthesia
and maintain its vitals during the study.
The back-end consists of the driving electronics shown in Figure 2-1.a. The RK-300
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arm goes into the bore of the MRI, while the driving electronics stay outside of the
MRI room.
(a) Driving Electronics (Back-End)
(b) The RK-300 Arm
Figure 2-1. The RK-300 at Johns Hopkins
Figure 2-2. Transducer and Focus Geometry
Software
The software, which provides a User Interface (UI) to the entire system, runs on a
PC (shown in Figure 2-3). Through this UI, the focus is registered and sonication is
performed with the desired parameters in the desired target location(s).
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Figure 2-3. User Interface of the Software
Accompanying Components
The following components accompany the system, and serve as accessories to a
particular task performed:
• Plastic sledge (Figure 2-4.a): Covers the transducer cavity, and serves as the
bed on which the phantom/animal can be placed.
• Membrane cuboid (Figure 2-4.b): The plastic sledge has a rectangular window
over the transducer to allow for the propagation of ultrasound. The membrane
cuboid is a coupling medium that covers this window to prevent water (that fills
the transducer cavity) from spilling while allowing the ultrasonic waves to pass
through.
• Bath (Figure 2-4.c): This is used in the process to register the focus.
• Focal marker (Figure 2-4.d): Appears hypointense (dark) in T1-weighted FLASH
MRI scans, and is used in the process of registering the focus.
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(a) Sledge (b) Membrane (c) Water Bath (d) Focal Marker
Figure 2-4. Accompanying Components
Experimental Design
The main aim of the experiment was to observe focus formation at the target using
the RK-300. To achieve this, an experiment was designed to focus ultrasound in a
solid water phantom.
Initial System Setup
The front-end was connected to the back-end of the system using a zero insertion
force (ZIF) connector. After ensuring the 1.0106 MHz impedance matching circuit
was connected, the system was turned on.
The hardware was then powered up, and the software was opened. One of the
first subsystems that the software checked was the motors that are used to perform
mechanical focus steering. The motors were visually observed to move the transducer
and settle into its home position. After the transducer settled into its home position,
the plastic sledge was attached. The transducer cavity was then filled with degassed
water (< 1 ppm of dissolved oxygen) up to the window opening. The membrane
cuboid was then placed over this water-filled transducer cavity (Figure 2-5). The
absence of air bubbles in the cavity was then visually confirmed.
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Figure 2-5. Membrane placed over the window of the bath filled with water
Registering the Focus
The main purpose of this step was to register the focus of the RK-300 (while
the transducer is in its home position) to the MRI. This means that the focus of
the transducer is recorded in MRI coordinates, and this is used to calculate relative
traveling distance to new target coordinates during treatment.
After ensuring the absence of air bubbles, a layer of degassed water was placed
over the membrane cuboid. The water bath was then slid over this layer of water.
Once again, the absence of air bubbles throughout the coupling path was ensured.
The bath was then filled with degassed water. In the software’s "Initialization Tab"
(Figure 2-6):
1. Under "Acoustic Parameters":
• The transducer (TX1) was selected
• A harmonic frequency of 1 was selected. The corresponding frequency of
1.106 MHz was reflected under "Frequency (MHz)"
2. Under "Focus Finding":
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• "Guided Focus Finding" was selected
• To the right, under "Step 1", the sonicate option was selected.
Figure 2-6. Registration Software Initialization Tab
After setting these parameters, a water fountain appeared on the surface of the
water in the bath. This corresponded to the focal region being formed by the transducer.
The water level was then adjusted until the sharpest focus, that is, the narrowest
fountain was observed (Figure 2-7.a). The focal marker was then placed over the
fountain, taped down, and the bath was filled with degassed water until there was
water in almost the entire column of the focal marker (Figure 2-7.b).
The prepped RK-300 arm was then placed into the bore of the MRI (with an
imaging coil in place). Care was taken not to spill water out of the water bath, and
the back-end was kept outside the MRI room.
The center of the water column of the focal marker was placed at the isocenter of
the magnet. Three-plane localizer images were acquired to ensure optimal positioning
and confirm the water level in the column. Coronal T1w FLASH scans were then
acquired. The parameters of the scan are provided in Table 2-I.
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(a) Focus forms a small
fountain in the water
bath (black arrow)
(b) Focal marker setup
Figure 2-7. Initial Setup and Focus Finding




Number of Slices 15
Slice Thickness 1 mm
Frequency Encode Direction S/I
Phase Encode Direction AP
Slice Gap 0
Field of View 60mm × 60mm
Acquisition Matrix 200 × 200
The coronal volume scans (2dseq file) were loaded into the RK-300 software. The
orientation of the MRI with respect to the image was read-in from the metadata, and
therefore, already accounted for in the software.
Using the interactive UI, the center of the cylinder (the focus) was set as the origin.
To do that:
• With the cursor over the MRI volume image set, we scrolled to navigate through
the slices.
• The green box was the limit of motor travel, and the blue square was the position
where the focus was currently targeting (Figure 2-8).
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• When the cursor was moved over the MRI slice image, a red crosshair at the tip
of the cursor was observed.
• The center of the cylinder was targeted. When the cursor was at the center of
the cylinder, a left-click was made.
• The red crosshairs were converted to a blue dot and a surrounding circle.
Figure 2-8. Loaded MRI scan to register the focus
Under "Step 3" of the "Guided Focus Finding", the "Set L/R" and "Set S/I" options
were selected. The L/R and S/I coordinates were observed to update on the left,
under "Focus Finding". The focus finding was then exited. Under "Focus Finding",
with the newly updated values of L/R and S/I, the "Confirm" option was selected.
On the right, the dark blue dot shifted to these coordinates (Figure 2-8). The system
(focus) was thus registered with the MRI coordinates, and ready to use.
Sonication in a solid water phantom
After registering the focus, the RK-300 arm was slid out of the magnet. The focal
marker and some water from the bath were removed. A solid water phantom from
CIRS Inc. was placed in the bath, and taped down (Figure 2-9).
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Figure 2-9. Solid-water phantom setup on the RK-300
This setup was then slid back into the bore of the MRI such that the center of
the phantom was, again, at the isocenter of the magnet. Three-plane localizer images
were acquired to ensure optimal positioning and the absence of air bubbles in the
coupling medium. Coronal and axial T1w FLASH scans were then acquired. The
parameters of the scan are provided in Table 2-II.




Number of Slices 15
Slice Thickness 1 mm
Slice Gap 0
Field of View 60mm × 60mm
Acquisition Matrix 200 × 200
Number of averages 4
The T1w axial scans were loaded into the RK-300 software. By scrolling through
the slices, the axial slice that had the central cross-section of the transducer was
selected. When the cursor is moved to different points in the image, the coordinates
23
corresponding to the cursor tip are reflected under the image. The cursor was moved
to the lip of the transducer below the plastic holder, and the vertical coordinate was
recorded. The focus of this transducer is geometrically fixed at 15.61mm. This value
was subtracted from the vertical coordinate to get the focal plane.
Figure 2-10. Treatment Planning: Axial View
The coronal scans were then loaded into RK-300 software. The slice corresponding
to the vertical coordinate of the focal plane was selected. This was the plane in which
we could target the focus of the ultrasound.
After selecting the single crosshairs tool under the "Treatment Planner" tab, the
cursor was moved to a desired target, and with a left click, the target was selected.
On the left, under the "Treatment" tab, the coordinates of the target appeared in the
table (Figure 2-11).
In the Treatment tab, the row with the target coordinates was first selected and
then "Go to Selected Target" was used to move the blue focal point to the red cross
hair (desired point). The motor moved the transducer such that focus was now at the
target point. This was verified by checking the status of the motors at the bottom
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(a) Selecting the target (b) Confirming the target
Figure 2-11. Treatment Planning: Coronal View
of the tab. The horizontal plane coordinates of the transducer was the same as the
target coordinates.
To sonicate, the "Continuous Wave" mode on the "Treatment" tab was selected, the
"Power" was set to 2 Watts, sonication time to 15 seconds and wait time to 10 seconds.
Single plane T1w FLASH axial scans were then acquired with the plane positioned at
the S/I coordinate. The parameters of the scan are provided in Table 2-III. A total of
15 scans were acquired - 2 before sonication, and the rest during and after sonication.
The scans put together (in post-processing) and showed a time sequence of the focus
forming at the target.




Slice Thickness 1 mm
Field of View 70mm × 70mm
Acquisition Matrix 128 × 128
Frequency Encode Direction AP
Number of Averages 1
Flip Angle 20 degree
In plane dimensions
(in plane resolution) 0.54 × 0.54
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Results and Discussion
During sonication, that is, the delivery of the acoustic energy to the focus, a
hyper-intense cone was seen from the surface of the transducer to the targeted focus
(Figure 2-13). This hyper-intense region was a result of molecules in the medium
vibrating under the influence of ultrasound. This was absent in the baseline scans
acquired just before sonication (Figure 2-12).
Figure 2-12. Pre-Sonication
Figure 2-13. During Sonication (hyper-intense cone marked in blue)
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Initially, an attempt was made to couple the phantom directly on the membrane
cuboid using degassed ultrasound gel, but air bubbles got trapped as the gel folded
over itself during application. Despite all attempts, an air bubble-free coupling
was not achieved. Since the absence of air bubbles was crucial to observe focus
formation, the phantom was immersed in the water bath which was then coupled
to the membrane cuboid. This caused bubble-free coupling from the transducer
to the phantom. However, it elevated the location of the phantom, such that, the
geometrically fixed focus was formed near the outer surface of the phantom, and not
well inside it. This was confirmed by the short axis and long-axis length of the tip of
the cone formed.
Conclusion
The RK-300 at the Department of Radiology was seen to successfully target a
location in a phantom, as observed by the single slice T1-weighted FLASH Time
Sequence Images. By observing this targeting, the RK-300 can be utilized to perform
a host of preclinical studies using different focused ultrasound applications.
This test can be used in Quality Control to ensure that the system is functioning
as intended. It can also be used as a standard operating procedure for first-time users
of the system.
Future Directions
Now that the RK-300 has been shown to successfully target a location inside a
phantom, its ability to target in vivo models can be validated. A simple experiment
to ensure correct targeting would be opening the BBB in a healthy rat (or mouse).
Successful targeting can be observed using T1-weighted images with Gadolinium
enhancement post treatment. The location at which the BBB is opened will be
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observed as a hyper-intense region (due to the uptake of gadolinium at the site). This
hyper-intense region can be cross-checked with the region targeted during treatment
planning. An overlap of these two regions will indicate successful targeting.
After correct targeting in an animal is achieved, the RK-300 can be used to
conduct any focused ultrasound application, with the exception of histotripsy (since
the transducer and driving electronics were not designed to provide the high voltages
required for histotripsy). A study to use the RK-300 to perform sonodynamic therapy
in a U251 glioblastoma rat model is currently underway.
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Chapter 3
Development of a Sensing System
to Monitor CSF Pressure
The application of transcranial focused ultrasound involves delivering energy at a
location inside the brain for a considerable duration of time. Therefore, care must
be taken to ensure that this application of energy does not cause any detrimental
downstream effects, one of which would be a deleterious increase in cerebrospinal fluid
pressure.
Cerebrospinal Fluid (CSF) is a liquid that surrounds and circulates throughout the
brain and spinal cord. It is responsible for not only cushioning the brain and spinal
cord, but also delivering nutrients, chemicals, and oxygen while removing waste [59].
An increase in CSF pressure in the brain is regarded as a medical emergency because
if left untreated, it can cause brain injury, stroke, coma, and death [60]. Therefore,
monitoring this pressure during therapies to the brain is crucial.
Here, we look at the development of a sensing system that can be used to monitor
CSF pressure in the brain (intracranial pressure). This system can be used to monitor
intracranial pressure before, during, and after focused ultrasound treatments in the
brain. By ensuring that CSF pressure does not dramatically change during or after
focused ultrasound treatment, the associated severe effects can be avoided, and
therefore, the safety of the treatment is assured.
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Selection of Pressure Sensors
A pressure sensor consists of a transducer that can read the pressure of the medium
in which it is placed in, convert it into electrical signals, and then interpret these signals
as a numeric value. The composition of this transducer, and the principle it uses to read
the pressure varies. There are many pressure sensors available, such as potentiometric,
inductive, capacitive, piezo-based (piezoresistive and piezoelectric), reluctance, and
fiber optics-based pressure sensors [61]. The two most common pressure sensors used
in medicine are piezo-based pressure sensors and fiber optics-based pressure sensors.
Piezo-based Pressure Sensors
Piezo-elements are materials whose electrical properties change when force is
applied to them. These can be further classified as piezoresistive and piezoelectric
elements.
In a piezoresistive element (also known as a strain gauge) experiences a change in
resistance when subjected to an applied force [62]. Therefore, if these materials are
arranged in a Wheatstone Bridge configuration, as seen in Figure 3-1, the change in
resistance corresponds to a change in the output voltage across the Bridge. There-
fore, pressure can be measured as a function of voltage. Piezoresistive elements are
commonly made up of germanium, polycrystalline silicon, amorphous silicon, silicon
carbide, or single crystal silicon [63].
A piezoelectric element (such as quartz, PZT or PMNPT), is a material that
generates a voltage when it experiences stress (as a result of pressure applied) [64].
This generated voltage is transient in nature, and is only generated during a change
in the applied stress [65]. The advantage of this element is that it acts as a voltage
source (which is a function of pressure), and therefore, does not require a voltage
source setup for measuring pressure. The disadvantage, however, is that it cannot
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Figure 3-1. The strain gauge is attached to a diaphragm. When the diaphragm deflects,
as a result of pressure, the resistance of the strain gauge changes
be used to continuously measure a constant pressure, but rather can only measure
changes in pressure.
Management of intracranial pressure measurement requires continuous measure-
ments of varying pressure and constant pressure, leading to piezo-resistive elements
being commonly used
There are three broad methods of placing the piezo-resistive sensor to measure
intracranial pressure:
• In the brain parenchyma
• Between the brain parenchyma and dura
• In the ventricles
These sensors are accurate, but their readings drift from the true value due to
their sensitivity to temperature [66, 67]. They also have a relatively larger form
factor (sensor size) for higher pressure sensitivity and lower power requirements [68].
However, these shortcomings are not exhibited by fiber optics-based pressure sensors.
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Fiber Optics-based Pressure Sensors
General Principle of Fiber Optics:
Light is an electromagnetic wave that consists of an electric and magnetic field
traveling mutually perpendicular to each other (Figure 3-2). Therefore, light can be
treated as a ray - a straight line with both magnitude and direction.
(a) Mutually perpendicular electric and magnetic
fields (b) Resulting light wave
Figure 3-2. Light as an electromagnetic wave
When light travels from an optically denser to rarer medium, it bends away from
the normal (dark blue vector in Figure 3-3.a), that is, a perpendicular drawn at the
interface of the surface. As the angle of the light in the denser medium increases, the
corresponding angle in the rarer medium increases, till at one point, light in the rarer
medium travels along the denser-rarer medium interface (neon-green vector in Figure
3-3.a). The corresponding angle in the denser medium is called the critical angle (θc
in Figure 3-3.a). When light is incident at a denser-rarer medium at an angle greater
than the critical angle, it is completely reflected back into the denser medium (red
vector in Figure 3-3.a). This principle is known as total internal reflection and is used
to propagate light in a fiber optic cable [69].
A fiber optic cable has a core and cladding. The core is made up of a material with
optical density greater (higher refractive index) than that of the cladding. Therefore,
if light enters the fiber in a suitable fashion, it will keep hitting the core-cladding
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interface at an angle greater than the critical angle. Therefore, light will bounce off
the walls of the fiber, as it propagates along the fiber [69] (Figure 3-3 (b)).
(a) Total internal reflection (b) Light propagation in a fiber
Figure 3-3. Total internal reflection and light propagating along a fiber optic
In addition to the cable, fiber optic sensor system is made up of a sensor and a
signal conditioner. The signal conditioner consists of a light source, and a detector.
The light source sends light to the sensor through the fiber optic cable, the light
interacts in the sensor, and the detector interprets the light reflected back from the
sensor. The sensor that lies on the tip of the fiber varies based on the physical
phenomenon being measured. Pressure is measured using the Fabry-Pérot Cavity.
Fabry-Pérot Cavity
The Fabry-Pérot Cavity can be used to measure the pressure of the medium in
which it is placed. As seen in Figure 3-4, the sensor is made up of a vacuum chamber
and two partially reflective surfaces on either side. The outer surface is a partially
reflective diaphragm (flexible membrane) while the inner surface is fixed. Light from
the source propagates through the fiber and is first incident on the inner surface.
Some light is partially reflected off that surface back to the detector, and the rest
of the light is in turn reflected from the diaphragm. The reflected light beams from
both the surfaces have a phase difference, which causes an interference pattern on the
detector (in this case an interferometer). In response to the environment’s pressure, the
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diaphragm deflects, and the distance between the two surfaces changes. Therefore, the
interference pattern changes. The initial distance is calibrated to a particular baseline
pressure, and subsequent changes in distance correspond to changes in pressure from
this baseline [70].
Figure 3-4. Fiber tip comprising the Fabry-Pérot Cavity (reproduced with permission
from [70])
Since the Fabry-Pérot based Fiber Optic Sensor has a smaller form factor (size) than
piezo-resistive sensors, it is an interesting option to explore for measuring intracranial
pressure for prolonged durations of time.
FOP-M260 by FISO
The FOP-M260 sensor by FISO is a Fabry-Pérot based Fiber Optic Sensor used to
measure pressure [70]. It is conventionally placed in a catheter which is inserted into
the target region in the body where pressure needs to be monitored. It consists of a
fiber optic cable with the Fabry-Pérot Cavity at the tip of the cable (Figure 3-5). A
polyimide tubing encloses the fiber optic. This tubing conventionally covers the entire
cable including the sensor tip. After the fiber optic has been successfully threaded
into the catheter, the polyimide tubing can be pulled back to expose the sensor tip.
Therefore, the polyimide tubing serves as protection to the sensor and fiber optic
cable.
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Figure 3-5. FOP-M260 Sensor Schematic (reproduced with permission from [70])
The fiber optic cable is connected to the signal conditioning module using a
SCAI connector. As previously mentioned, the signal conditioner houses the light
source and the interferometer. The signal conditioner can be connected to a laptop
using a USB connector. The Evolution software by FISO, installed on a laptop,
serves as the processor and user interface. It can be used to calibrate the sensor
(the FOP-M260 was calibrated by the manufacturer using a polynomial regression
algorithm, where Pressure = 14.52103 − 0.01429 ∗ (internalreading − center)1 +
2.67E − 06 ∗ (internalreading − center)2 − 1.93E − 09 ∗ (internalreading − center)3)
, set atmospheric pressure to zero, and read out values from the signal conditioner.
The pressure value recorded can be stored and used for data analysis.
(a) FISO Pressure Signal Conditioning Module (b) FISO Pressure Sensing Configuration
Figure 3-6. FISO pressure sensing module and user interface (reproduced with permission
from [70])
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The parameters as listed in Table 3-1 make it suitable for measuring intracranial
pressure, and is therefore the sensor we will be testing with the end-goal of using it to
measure intracranial pressure.
Table 3-I. Specifications of the FOP-M260 by FISO
Parameter Value
Outer Diameter (sensor tip) 0.26 mm
Outer Diameter (with polyimide tubing) 0.31 mm
Bare Fiber Length 2 m
Polyimide Tube Length 2 m
Pressure Range
(relative to atmospheric pressure) -300 mmHg to +300 mmHg
Resolution < 0.3 mm of Hg
Operating Temperature Range 15°C to 45°C
Long Term Bending Radius (Minimum) 17 mm
Sterilization Method Ethylene oxide sterilization (EtO)
Sampling Frequency 250 Hz
Epoxy Coating Yes, just not on sensor tip
Used in medical applications Yes
System Requirements
The testing to be conducted on the pressure sensor was driven by the requirements
outlined in Table 3-II. The performance requirements were determined by existing
standards for pressure sensors, and discussions with clinical experts. Table 3-II
provides an overview of the sensor requirements and the test to be conducted to verify
the requirements. The following sections will describe the testing procedures in greater
depth and the results of the testing.
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Table 3-II. System Requirements
Number Type Description Testing Method
1 Performance
The sensor shall be able to
maintain pressure readings within
the specified resolution for up to
hours Drift testing
2 Performance
The sensor shall be able to
maintain pressure readings within
the specified resolution as




The sensor shall maintain
readings with the specified
resolution while experiencing a
bend radius of 17 mm Bend Radius testing
4 Performance
Overall Sensor Range shall be
between 1 to 40 mmHg with a
resolution ≤ 1mmHg Accuracy testing
Experimental Design
Initial testing was carried out to ensure that the acquired COTS (commercially
available off-the-shelf components) sensor met the system requirements. For this
testing, a hydrostatic water column setup was utilized. Pressure was be determined
by water increments in the column and can be calculated by the equation below.
P = ρ × h × g
Where, P = pressure (pascal); ρ = density of water, which is 999.9kg/m3; h = height
in the water column (in meters); g = acceleration due to gravity, which is 9.8m/s2
P = 999.9 × h × 10−2 × 9.8
P = (97.99 × h)Pascals
P = 97.99h133.32 mmHg = (0.7h)mmHg
The image below (Figure 3-7) highlights the experimental setup used for the
preliminary testing. A 4000 ml hydrostatic column was used. This allowed for absolute
pressures (not relative to the atmospheric pressure) from 0 mmHg to 40 mmHg. The
37
fiber optic was fixed such that the sensor tip was close to the bottom of this column.
Then the pressure was varied by varying the height of the column while leaving the
sensor in place. The main aim of the tests conducted was to verify the optical fiber
sensor when tested met specified requirements and manufacturer specifications. The
tests described are influenced by the ANSI/AAMI NS28:1988/(R)2010 for Intracranial
pressure monitoring devices.
Figure 3-7. ACMI Test-Bench Setup
Drift Test
Zero drift testing for pressure sensors help us understand if zero drift occurs in
the beginning during the settling period or if long term use causes deterioration of
functionality. For this test, the sensor was left in the box in which it came. This
served as a simple method to hold the sensor in place. The polyimide tubing was slid
back to expose the sensor (the sensor is generally covered by the polyimide tubing to
protect it). The lid of the box was placed over the sensor except for some room to
allow the proximal end of the fiber optic to connect to the signal conditioner sitting
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outside the box. The pressure of the sensor inside the box was recorded at a sampling
frequency of 250 Hz for 24 hours. The recorded pressure was then passed through a
low pass filter with a cutoff frequency of 1 Hz (since static pressure is being measured)
and then plotted as a function of time.
Temperature Stability of Measurement
This test aims to evaluate the performance of the pressure sensor under varying
temperature conditions. The column was filled up such that the height of the water
column above the sensor was 10 cm. In this test, the water used to fill the hydrostatic
column was about 42°C. This temperature was confirmed used a negative temperature
coefficient thermistor-based temperature sensor. This temperature sensor was then
placed inside the hydrostatic column to monitor temperature. The pressure was then
recorded as the temperature naturally cooled down to a temperature of 27°C. This
test was repeated for a water column height of 19 cm. The pressure reading was
expected to stay constant as temperature varied.
Accuracy Test
For this testing, a hydrostatic column was used. Using the hydrostatic column
allows for the pressure exerted by the column to be calculated (as discussed above).
These calculations serve as a ’reliable’ reference sensor.
The pressure of the hydrostatic column was varied from 2 cm to 40 cm inches
in 2 cm increments. The pressure at each level was recorded by the pressure sensor
for 5 minutes in triplicates. The pressure difference between each successive pressure
recorded was then calculated. The pressure difference between each successive reading
should be 1.4711 mmHg. This difference was used to verify accuracy of the system.
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Bend Radius Testing
To position the pressure sensor, it is placed in a catheter, and the catheter is
threaded to the target location. As the catheter is threaded to the target location, it
is often bent. With fiber optics, bending the fiber optic such that its bending radius
is less than the minimum bending radius for the core-cladding combination risks
breaking the fiber as well as affecting the light path to and from the sensor tip, and
therefore, affect the pressure reading. The effects of exceeding the minimum bending
radius include:
• Higher attenuation
• Damage to the cable structure
• Possibility of breaking the fiber
The FOP-M260 by FISO has a manufacturer recommended minimum long-term
bending radius (the minimum radius the fiber can be deformed to prolonged periods )
of 17 mm.
The pressure in the column was maintained at a water column height of 34 cm
above the sensor. The fiber was then looped such that it was 30 mm, 17mm, and 8.5
mm (in three separate cases), and the pressure was recorded for 1 hour.
Results and Discussion
Zero Drift Test Results
The sensor showed no significant variation (drift) over 20 hours with a slight
decrease (about 3 mmHg) in the last four hours of recording (Figure 3-8). This dip
in pressure towards the end could have been a result of changing weather conditions,
since the pressure sensor can pick up even the slightest change in pressure.
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The pressure sensor readings did not drift significantly. However, the slight decrease
in pressure towards the end of the test period needs to be further investigated. This
can be done by repeated testing, or testing zero drift in a hydrostatic column to
minimize the effect of changes in atmospheric pressure).
Figure 3-8. Pressure Sensor Zero Drift Test Results
Temperature Stability of Measurement Test Results
As seen in Figure 3-9, the pressure decreased by about 4mmHg (in both the cases)
during the first 30 seconds and remained constant for the remaining duration of the
test. Therefore, the stability of measurement results met our system requirements
with pressure not varying significantly as temperature of the water column it was
placed in varied.
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(a) Relative Pressure at 19 cm (b) Relative Pressure at 10 cm
Figure 3-9. Stability of measurement tests results
Accuracy Test Results
For accuracy of the system, since the pressure sensor measured pressure relative to
atmospheric pressure, a change in pressure between successive readings was used to
verify accuracy of the pressure recorded by the sensor.
In Figure 3-10, the blue line graph shows the increase in pressure with increase
in height of the water column. The black error bars correspond to the deviation
of changes in pressure from 1.4711 mmHg. The numeric values of these errors are
provided in Table 3-III. Since 2 cm was the first value recorded, the recorded pressure
difference from a previous value cannot be calculated, and therefore, its recorded error
is assumed to be zero.
The average error calculated was 0.227 mmHg. This met the accuracy requirements
for our application. The largest error was recorded at 6cm with a 1.11 mmHg difference.
This was not a concern since variation was expected based on how the test was
conducted, that is, the height of the water column was measured manually.
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Figure 3-10. Pressure Sensor Accuracy Test Results
Table 3-III. Pressure Sensor Accuracy Testing
Water column height (cm) Measured Difference (mmHg)
2 0
2 - 4 -0.8256
4 - 6 -1.1168
6 - 8 -0.0333
8 - 10 -0.2652
10 - 12 -0.8149
12 - 14 -0.2502
14 - 16 0.0370
16 - 18 0.1370
18 - 20 0.2177
20 - 22 -0.0392
22 - 24 -0.0650
24 - 26 0.0157
26 - 28 -0.0979
28 - 30 -0.3242
30 - 32 0.0926
32 - 34 -0.0168
34 - 36 -0.0466
36 - 38 -0.1041
36 - 40 0.0486
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Bend Radius Test Results
The sensor performed as per manufacture specifications when the bend radius of
the fiber optic was held at 17mm and 30mm, respectively. Despite the manufacturer
recommending that the bend radius of the fiber not be held under 17 mm, the recorded
pressure value varied from the above values by 1 mmHg when the bend radius of the
fiber was held at 8.5 mm during data acquisition (Figure 3-11).
Figure 3-11. Bend Radius Test Results
Conclusion
By passing the preliminary round of testing, the Fabry-Pérot - based Fiber Optic




After successful bench-top testing, the immediate step would be to replace the
hydrostatic column with a pulsed pressure generator regulated system, and repeat all
the tests conducted above. This is because the intracranial pressure is pulsatile, and






Focused ultrasound is ushering in an exciting era of non-invasive and effective
treatments for brain diseases. The literature reflects this increase in research in the
field with great promise of translatable treatments. Thermal ablation to treat essential
tremor has been FDA approved, along with opening the BBB for drug delivery in the
treatment of Parkinson’s disease. In addition to these approved treatments, the FDA
has approved BBB opening to treat brain tumors and Alzheimer’s disease. These
approved treatments and clinical treatments are only the beginning for translatable
applications.
All these clinical trials are built on the foundation of rigorous animal studies. The
RK-300 by FUS Instruments has proven to be vital in different focused application
studies in small animals. It is versatile in the applications of focused ultrasound it
can support. It has been instrumental in studies using focused ultrasound to perform
thermal ablation, BBB opening for drug delivery, and sonodynamic therapy. The
system cannot be used to observe histotripsy in the treatment of brain tumors because
the transducer and driving electronics cannot support the high voltages that are
necessary to produce the high peak pressure in vivo. However, the applications the
system can perform, makes it a vital tool in preclinical studies.
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Safety in these treatments is important - these treatments should not cause
any downstream effects. In applications of focused ultrasound in the brain, the
cerebrospinal fluid is an important parameter that should be monitored especially as
focused ultrasound establishes itself as a form of therapy. The Fabry-Pérot Cavity
- based pressure sensor by FISO shows great promise in being used as a minimally-
invasive method to measure intracranial pressure. The fiber optic system tested
here was demonstrated to meet all the manufacturer’s standards. Additionally, by
successfully passing the zero-drift, accuracy, bend radius, and stability of measurement
test, the FOP-M260 by FISO is an excellent candidate to measure intracranial pressure
before, during, and after focused ultrasound-based treatments.
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Where is Focused Ultrasound
heading?
Focused ultrasound is progressing, especially for treating brain diseases. It is
already utilized for the treatment of essential tremor and Parkinson’s Disease. In the
near future, we will see it being used in the treatment of brain tumors (using histotripsy,
blood-brain barrier opening - aided chemotherapy), and Alzheimer’s Disease.
Preclinical studies form the backbone of translation. There is a lot of research on
designing and improving the instruments used for pre-clinical studies. For example,
when it comes to the RK-300, work is being done to better integrate the RK-300 with
the MRI system. The version of the RK-300 that was used for the phantom test is
an earlier version of the software that is currently sold with the system. While using
the earlier version of the software, the RK-300 has to be slid in and out of the MRI
twice - once to register the focus of the system and the second time, to carry out the
treatment. When the RK-300 is slid back into the magnet for treatment, if it is not
placed at the same position in the magnet as before, an error is introduced, and this
error will affect the coordinates of the desired focus target(s). The new version of the
software that is sold with the system eliminates the need to slide the arm out of the
RK-300 for a particular animal study, therefore, allowing for better accuracy in focus
targeting.
Concerning potential measurement of intracranial pressure, as mentioned earlier,
the Fabry-Pérot Cavity-based pressure sensor by FISO shows great promise. The
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successful preliminary testing has set the stage for more rigorous testing for translation
to the clinic. Since intracranial pressure is pulsatile, the tests performed (with the
exception of the zero drift test), need to be performed with pulsatile pressure. This
can be done by swapping out the hydrostatic column with a closed system where
a pulsed pressure generator regulates the pressure. After this has been successfully
performed, progress can be made to small animal studies followed by larger animal
studies and then clinical trials.
In conclusion, research in the field of focused ultrasound is progressing at a rapid
pace. With surgeons and engineers working together, it will not be long before focused
ultrasound is treated as a "conventional" therapy or maybe even in the "gold standard"
in treating certain diseases.
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    •  Using the RK300 to perform MRI-guided focused ultrasound (single-point, multi-point, and multiple-treatment)  
    •  Measuring the effect of the treatment on tumor volume, survival time, CSF pressure 
 
•  Design of the Acute CSF Management Implant (ACMI), HEPIUS System of Systems (DARPA Grant) – In Progress                          
    Collaboration: JHU Applied Physics Laboratory 
    •  Schematic design of the ACMI’s pressure sensor 
    •  Preliminary and critical design review of the ACMI’s pressure sensor 
    •  Complete hardware prototype of the implant 
    •  Design of the experimental setup for proof of concept verification of the prototype  
 
•  Ultrasound Imaging to detect and subsequently prevent cotton ball retention in neurosurgery           
    •  Porcine cadaver ex-vivo studies to detect cotton balls of various sizes and at various depths of the brain parenchyma 
   •  CAD (using SolidWorks) and 3D printing (using the Object) of a depth dox 
    •  Using the Clarius and Butterfly ultrasound probes to collect B-mode images   
 
•  Design of a custom 3D printed ultrasound probe holder to reduce noise induced by handheld movement – In Progress                     
    •  CAD (using COMSOL) and 3D printing of the probe holder 
    •  Animal (porcine) translational studies to validate the improvement in image quality on imaging with the probe holder 
 
SMARTS Lab, Johns Hopkins University                                                                                                                           (Sept 2019 – Feb 2020) 
Instrument Tip Force Measurement & Verification for Application in Surgical Robotics 
• Built the entire experimental setup that included two force sensors and a UR3 Arm 
• Collected and analyzed data from the two sensors to verify the estimated forces at the tool tip and phantom-end using ROS and MATLAB 
 
 
TEACHING AND ADMINISTRATIVE EXPERIENCE 
Teaching Assistant                                                                                                                                                                      (Jan 2021 – present) 
Applied Bioelectrical Engineering, Department of Biomedical Engineering, Johns Hopkins University                                                            
•    Conduct office hours to assist students with understanding concepts of the course 
•    Assist the professor with designing questions for the group discussions, homeworks and quizzes 
 
Teaching Assistant                                                                                                                                                                 (Sept 2020 – Dec 2020) 
Principles of Design of Biomedical Instrumentation, Department of Biomedical Engineering, Johns Hopkins University                                                            
•    Designed and graded the lab component of the course   
•    Performed remote demonstration of the labs and sample projects 
•    Conducted lab hours and office hours to assist students with the lab (remote debugging) and theory component of the course 
   
 
Graduate Assistant                                                                                                                                                                    (Jan 2020- Apr 2020)                                                                                                                  
Centre for Diversity & Inclusion, Johns Hopkins University                                                                                                               
• Organized logistics and analyzed data for the Identity & Inclusion Workshops   
 
PROJECTS 
Bio-Gaming Control for Bilateral Below-Elbow Amputees                                                                                                            (Nov 2019) 
• Wrote a microcontroller-based algorithm to implement keystroke based on inputs from multiple sensors 
• Assembled and integrated all electrical components into the system 
 
Control Scheme Implementation on a UR5 Arm for Home to Target Configuration Transition                                                     (Nov 2019) 
• Implemented the Gradient-based control scheme using MATLAB and ROS 
 
Wearable Foetal Activity Counter                                                                     (Oct 2019) 
• Designed a microcontroller-based system using the piezo transducers as the sensors 
• Assembled and integrated all the components into the system 
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A Mechanism Using Shape-Memory Alloys to Assist Affected Limb Motion in Partially                                            (Sept 2018 – May 2019) 
Paralyzed Patients   
• Framed the outline of the entire mechanism and simulated the required joint angles in OpenSim 4.0  
• Designed the entire electronic interface and integrated it into the mechanism 
 
Team SRMSAT - Design of a Micro-class Satellite to be Launched into Space                                                              (Aug 2016 – May 2019) 
• Designed and implemented a robust Attitude Control System to achieve the desired pointing accuracy required by the spacecraft during its 
various functional and operational modes in MATLAB Simulink 
Electrical Reconfiguration of a Partially Shaded P.V. System Using Proposed Intelligent Series Inducing Switching         (Feb – Apr 2018) 
• Designed the switching method to electrically configure PV panels that optimizes power output during partial panel-shading 
• Simulated the system using MATLAB Simulink 
 
PUBLICATIONS 
• Smruti Mahapatra et al, ‘Automatic detection of cotton balls during brain surgery: where deep learning meets ultrasound imaging 
to tackle foreign objects’, Proc. SPIE 11602, Medical Imaging 2021: Ultrasonic Imaging and Tomography, 116021C (26 February 2021); 
DOI: 10.1117/12.2580887 
• Tarana Parvez Kaovasia, Siddharth Dash, ‘A novel portable device used to perform autologous blood transfusion in an unsterilized 
environment’, 4th World Congress on New Technologies, ICBB'18, August 19-21, 2018. DOI: 10.11159/icbb18.103 
 
• Tarana Parvez Kaovasia, Siddharth Dash, ‘A mechanism using shape-memory alloys to assist partially paralyzed patients in walking 
with a natural gait’, 4th World Congress on New Technologies, ICBB'18, August 19-21, 2018. DOI: 10.11159/icbb18.105 
 
• A Geetha et al, Electrical Power Generation and Storage System in Electric Vehicle–An Overview, International Journal for Control 




• Software: MATLAB Simulink, COMSOL, PSPICE, LabVIEW, AutoCAD, TINA, Arduino, SolidWorks, Fusion360, 3D Slicer     
• Design: PCB Fabrication, 3D Printing        •    Programming Language: MATLAB, C++, ROS, Python  
•  
HACKATHONS 
•  FixingBad, HopHacks, Johns Hopkins University                                                                                                     (Sept 2020) 
    •  Prototyped a simple website that is operable by the average user and directly validates information about COVID-19 without 
         producing confusing results 
   •  Achievements: Hacking- Runner Up, Best Use of Google Cloud - COVID-19 Hackathon Fund, Winners of DigitalOcean,  
        Best Application to Support Philanthropic Goals (Bloomberg) 
   •  Devpost link: https://devpost.com/software/fixing-facts-5iks7x 
 
•  FireHacker, MedHacks, Johns Hopkins University                                                                                                (Sept 2020) 
    •  Prototyped a sensor-based approach to alert older individual’s about unattended cooking stoves 
   •  Devpost link: https://devpost.com/software/fire-hacker 
 
•  COVID-19 Risk Assessment Tool, COVID-19 Design Challenge, Johns Hopkins University                                                           (Mar 2020) 
    •  Prototyped an app using a real-time risk assessment model coupled with human traffic monitoring 
 
INTERSHIPS 
Winter Intern                                          (Dec 2017) 
Cummins India Office                                                                                                 Pune, India 
• Observed and learned the various aspects of Wiring Harness Systems as used in automobiles 
 
Product Test Intern                                                            (Jun - July 2016) 
EMI/EMC Lab, Research Centre Imarat, DRDO                                                                                                                              Hyderabad, India 
• Gained first-hand experience of industrial grade product testing and defence-based projects 
 
LEADERSHIP SKILLS 
• Member - LGBTQA Graduate Advisory Board, Johns Hopkins University (2020 – Present) 
• Organizer - The Quality Assurance Committee, Aaruush’18, SRMIST                                                                                       (2018 – 2019) 
• Joint Secretary - EEE Association, SRMIST                                                                                                                                (2017 – 2018) 
• Soccer Representative - Represented Maharashtra in soccer at the 56th and 57th National School Games                                (2010 – 2012) 
•  
SCHOLARSHIPS 
•  25th Anniversary FEZANA Endowed Scholarship for Excellence                                                                                                      (2020-2021) 
•  Vakhshoori Foundation Scholarship                                                                                                                                                    (2019-2020) 
•  R.D. Sethna Scholarship Awardee                                                                                                                                                       (2019-2020) 




Tarana was born in Mumbai and brought up in Pune, India. Growing up, her
family played an important role in exposing her to a variety of experiences, in addition
to supporting her in endeavours of her own. This is the primary reason why she has
played soccer at a national level along with training in piano, swimming, horse-back
riding and roller skating. The importance of working towards achieving what she
wanted was imbibed into her from the very beginning.
She is interested in the design and development of devices and therapies to augment
the healthcare system through innovation and the application of new technologies.
With a background in Electrical and Electronics Engineering, she is pursuing her
Master’s in Biomedical Engineering at Johns Hopkins University. Her current research
is in the field of focused ultrasound and smart sensing. After graduating, she will be
continuing her research in the field of focused ultrasound during her Ph.D. studies.
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